Cargando…
Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan
Autores principales: | Zanichelli, Andrea, Wu, Maddalena, Cicardi, Marco, Vacchini, Romualdo, Bonanni, Erika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406533/ http://dx.doi.org/10.1186/1939-4551-8-S1-A173 |
Ejemplares similares
-
The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews
por: Jean-Baptiste, Milenka, et al.
Publicado: (2022) -
Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study
por: Zanichelli, Andrea, et al.
Publicado: (2018) -
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019) -
Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012) -
Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
por: Tyson, Christopher, et al.
Publicado: (2019)